Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vaxart, Inc

0.4442
+0.01904.47%
Volume:1.64M
Turnover:703.04K
Market Cap:101.26M
PE:-1.34
High:0.4500
Open:0.4201
Low:0.3899
Close:0.4252
Loading ...

BRIEF-Vaxart Completes Enrollment In Phase 1 Trial For Its Norovirus Oral Pill Vaccine Candidate

Reuters
·
Yesterday

Vaxart Inc - Topline Data From Phase 1 Trial Expected Mid-2025

THOMSON REUTERS
·
Yesterday

Vaxart Inc - Plans Phase 2 Study for Norovirus Vaccine in Second Half 2025

THOMSON REUTERS
·
Yesterday

Vaxart Inc - Phase 3 Trial for Norovirus Vaccine Could Begin in 2026

THOMSON REUTERS
·
Yesterday

Vaxart Completes Enrollment in Phase 1 Trial for Its Norovirus Oral Pill Vaccine Candidate

THOMSON REUTERS
·
Yesterday

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

GlobeNewswire
·
Yesterday

Pharma Stocks Sink After Trump Says "Major" Tariffs Are Coming

Tiger Newspress
·
09 Apr

Pharma Stocks Survive Market Rout on Tariff Exemption, but Uncertainty Continues

Reuters
·
03 Apr

Pharma Stocks Sink After Ouster of Top FDA Vaccine Regulator

Reuters
·
31 Mar

BRIEF-Vaxart Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
27 Mar

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
27 Mar

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
27 Mar

B. Riley Cuts Price Target on Vaxart to $2 From $2.50, Keeps Buy Rating

MT Newswires Live
·
27 Mar

Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
22 Mar

BRIEF-Vaxart Inc to offer up to $50 mln of common stock

Reuters
·
22 Mar

Q4 2024 Vaxart Inc Earnings Call

Thomson Reuters StreetEvents
·
21 Mar

Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ...

GuruFocus.com
·
21 Mar

VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
21 Mar

Vaxart Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
21 Mar

BRIEF-Vaxart Provides Business Update And Reports Full Year 2024 Financial Results

Reuters
·
21 Mar